Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q5VV17
UPID:
OTUD1_HUMAN
Alternative names:
DUBA-7
Alternative UPACC:
Q5VV17
Background:
OTU domain-containing protein 1 (OTUD1), also known as DUBA-7, plays a crucial role in cellular processes by specifically hydrolyzing 'Lys-63'-linked polyubiquitin to monoubiquitin. This action is vital for the stability and translation of mRNAs rich in rare codons, through deubiquitination of the 40S ribosomal protein RPS10/eS10. OTUD1's activity counteracts ZNF598-mediated ubiquitination, ensuring efficient translation and preventing ribosome quality control (RQC) pathway activation.
Therapeutic significance:
Understanding the role of OTU domain-containing protein 1 could open doors to potential therapeutic strategies.